Cardiovascular Risk Assessment after Sofosbuvir and Daclatasvir Regimen for Chronic Hepatitis C Virus Infection

Objective: To assess cardiovascular risk after sofosbuvir and daclatasvir antiviral combination therapy in chronic hepatitis C virus patients.Methods: The prospective cohort study was conducted at the Kafrelsheikh University Hospital, Egypt, from December 2019 to 2021, comprised adult patients of either gender with minimum ejection fraction 40%. They were classified into groups according their risk. Group 1 had individuals no factors, 2 many 3 only hypertension, 4 those diabetes alone, 5 smokers. All evaluated for major events baseline end 12-week 400 mg once daily dose 60 dose. Data analysed SPSS version 23.Results: Of 200 patients, there 96(48%) males 104(52%) females. age ranged 34-81 years. There 78(39%) 1; 20(25.6%) 58(74.4%) females mean 54.4±10.45 60(30%) patients; 40(66.6%) 20(33.3%) 59.57±9.1 25(12.5%) 3(12%) 22(88%) 61.4±7.8 13(6.5%) 10(77%) 3(23%) 55.4±10.4 24(12%) who all (100%) 60.7±5.7 non-significant changes incidence angina, arrhythmias or progression dyspnoea (p>0.05). Echocardiography follow-up results showed meanejection fraction, global longitudinal strain pulmonary artery pressure (p>0.05).Conclusion: Sofosbuvir found be safe regarding cardiac risks.Keywords: Sofosbuvir, Daclatasvir, Stroke, Pulmonary, coronary syndrome, Cardiovascular, Hepatitis C, Ventricular dysfunction, Echocardiography, Amiodarone, Hypertension, Arrhythmias, Diabetes, Dyspnoea, Smoking.